We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · July 17, 2021

Higher Baseline hs-TnT May Identify Potential Benefit From Sacubitril/Valsartan in HFpEF

JACC: Heart Failure


Additional Info

JACC: Heart Failure
Integrating High-Sensitivity Troponin T and Sacubitril/Valsartan Treatment in HFpEF: The PARAGON-HF Trial
JACC Heart Fail 2021 Jun 29;[EPub Ahead of Print], M Gori, M Senni, B Claggett, J Liu, AP Maggioni, M Zile, MF Prescott, DJ Van Veldhuisen, F Zannad, B Pieske, CSP Lam, J Rouleau, P Jhund, M Packer, MA Pfeffer, M Lefkowitz, V Shi, JJV McMurray, SD Solomon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading